NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report released on Monday morning,Benzinga reports. D. Boral Capital currently has a $34.00 target price on the stock.

NRXP has been the subject of a number of other reports. Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. HC Wainwright increased their price objective on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

NRx Pharmaceuticals Stock Up 11.8%

NRx Pharmaceuticals stock opened at $2.08 on Monday. The stock has a 50-day moving average price of $1.99 and a 200 day moving average price of $2.46. The company has a market capitalization of $66.29 million, a price-to-earnings ratio of -0.89 and a beta of 1.97. NRx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $3.84.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Anson Funds Management LP grew its stake in shares of NRx Pharmaceuticals by 50.3% during the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after purchasing an additional 1,018,853 shares during the period. Vanguard Group Inc. lifted its stake in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares during the period. Commonwealth Equity Services LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter worth $994,000. AdvisorShares Investments LLC boosted its holdings in NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in NRx Pharmaceuticals by 17.8% during the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after buying an additional 33,004 shares during the period. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.